Accumulating evidence suggests that GLP‐1 RAs show promise in the treatment of NAFLD, although there are few therapeutic studies with biopsy‐confirmed liver histological change as the primary end‐point. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.